Your doctor should be following this up so you have a baseline measurement before you get dementia/Alzheimers.
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.
3. A 20% chance in this research. July 2013.
If you have anything close to a decent doctor a protocol will already be in place to prevent this from occurring.
http://medcitynews.com/2016/07/imaging-visualization-alzheimer/?utm_source=hs_email&utm_medium=email&utm_content=31759017&_hsenc=p2ANqtz-9xRPeh25C-cuRq1WVy5tXJWE84eeVzTZXtOVLYArknaDLUeLJd1wdF44JRsmGuBun4dJuY_5ixWY1ujIdL5TvonMojIw&_hsmi=31759017
A nonprofit dedicated to finding a cure for Alzheimer’s disease
is funding a new technology that allows greater visualization of
amyloid plaques as well as other Alzheimer’s markers, such as tau
proteins and vasculature and microglia activation.
The technology was created by scientists at the New York City-based Fisher Center for Alzheimer’s Research Foundation and described in a study published in the scientific journal Cell Reports.
Dr. Marc Flajolet, lead author of the study and team leader, said the
new technology platform allows the visualization of those markers in
larger, three-dimensional amyloid patterns (TAPs) in greater volume.
Fisher Center scientists conducted their research on brain tissue from
mice and frozen human brain samples of deceased Alzheimer’s patients.
“We are proud that the funding we provide has resulted in innovative,
never- before-seen imaging of what causes Alzheimer’s disease,” said
Kent Karosen, Fischer Center president and CEO. “The Fisher Center
scientists are working diligently to better understand the cause and
cure of the disease and with the ability to visualize the causes of
Alzheimer’s, we’re one step closer to a cure.”
Flajolet said the Fisher’s team employed the “iDISCO” visualization
method involving targeted molecular labeling, tissue clearing and
light-sheet microscopy.
The new technology allows 3-D visualization in five different brain
regions, better mapping and automated detection enabling faster
quantification of plaques, which Flajolet characterized as a cheaper
alternative to standard beta amyloid plaque labeling.
“Now we can look at much bigger volumes and see bigger structures
that we could not see before in higher resolution,” he explained.
“Before this, there were more limitations. We were unable to get the
detail we get now.”
He said the technology may open doors of possibility for further
Alzheimer’s research that might lead to new Alzheimer’s disease
classifications.
“What we have discovered is that amyloid plaques (the groupings of
protein that mark the presence of Alzheimer’s) organize themselves into
strange patterns that are distributed in different ways, in some cases
layers of plaques,” he said. “We don’t yet understand the meaning. But
if we could organize patients by how those plaques presented themselves
in the brain through retrospective studies and learn the symptoms those
patients expressed, we might find ways to categorize stages of the
disease differently.”
He said that today, new drugs are tested on Alzheimer’s patients
without regard to the level or patterns of plaque in their brains.
“But perhaps, like depression or schizophrenia, not all patients
respond to the same drugs. Could it be the same for Alzheimer’s?”
Flajolet wondered. “If we are dealing with brains and we know patient
symptoms, there is a chance we could propose some categories so the next
clinical trial might be used on different patients expressing different
patterns. It might only work on 10 percent of patients, but it could
open doors.”
The Fisher Center for Alzheimer’s Research Foundation was established
in 1995 by philanthropists Zachary Fisher and David Rockefeller. Paul
Greengard, who leads the research center, is a Nobel Prize-winning
scientist, leads a team of 50 researchers seeking a cure for
Alzheimer’s.
Here’s a video from the Fisher Center demonstrating the visualization:
No comments:
Post a Comment